留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

慢性阻塞性肺疾病的药物治疗进展

陈开宇 江丽萍 陈盛新

陈开宇, 江丽萍, 陈盛新. 慢性阻塞性肺疾病的药物治疗进展[J]. 药学实践与服务, 2012, 30(6): 408-411. doi: 10.3969/j.issn.1006-0111.2012.06.003
引用本文: 陈开宇, 江丽萍, 陈盛新. 慢性阻塞性肺疾病的药物治疗进展[J]. 药学实践与服务, 2012, 30(6): 408-411. doi: 10.3969/j.issn.1006-0111.2012.06.003
CHEN Kai-yu, JIANG Li-ping, CHEN Sheng-xin. Progress on drug treatment of chronic obstructive pulmonary disease[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(6): 408-411. doi: 10.3969/j.issn.1006-0111.2012.06.003
Citation: CHEN Kai-yu, JIANG Li-ping, CHEN Sheng-xin. Progress on drug treatment of chronic obstructive pulmonary disease[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(6): 408-411. doi: 10.3969/j.issn.1006-0111.2012.06.003

慢性阻塞性肺疾病的药物治疗进展

doi: 10.3969/j.issn.1006-0111.2012.06.003

Progress on drug treatment of chronic obstructive pulmonary disease

  • 摘要: 慢性阻塞性肺疾病作为全球第四大死因,给公众的健康带来了严重威胁。适宜的慢性阻塞性肺疾病药物治疗能够预防和控制症状,减少急性加重的频率和严重程度,提高运动耐力和生活质量。合理使用作用机制不同、作用持续时间不同的药物,是当前慢性阻塞性肺疾病治疗的研究热点。本文综述近年来慢性阻塞性肺疾病的药物治疗进展及其治疗策略。
  • [1] GOLD Executive Committee.Guidelines:Global Strategy for the Diagnosis,Manage-ment,and Prevention of Chronic Obstructive Pulmonary Disease(Revised 2011) [DB/OL],(2011-01-21)[2012-03-18].http://www.goldcopd.org/.
    [2] World Health Organization.The World Health Report 2000-Health systems:improving performance[R/OL]. [2012-03-18]. http://www.who.int/whr/2000/en/index.html.
    [3] Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China:a large, population-based survey[J].Am J Respir Crit Care Med,2007,176:753.
    [4] Lopez AD, Murray CC. The global burden of disease, 1990~2020[J]. Nat Med,1998,4:1241.
    [5] Hogg JC,Chu F,Utokaparch S,et al.The nature of small-airway obstruction in chronic obstructive pulmonary disease[J].N Engl J Med,2004,350:2645.
    [6] Bestall JC,Paul EA,Garrod R,et al.Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease[J].Thorax,1999,54:581.
    [7] Rahman I.Oxidative stress in pathogenesis of chronic obstructive pulmonary disease:cellular and molecular mechanisms[J].Cell Biochem Biophys,2005,43:167.
    [8] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2007修订版) [J].中华结核和呼吸杂志,2007,46:254.
    [9] Schols AM,Soeters PB,Dingemans AM,et al.Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation,Am Rev Respir Dis,1993,147:1151.
    [10] 卫生部办公厅.慢性阻塞性肺疾病诊疗规范(2011年版)[EB/OL]. (2011-08-12)[2012-03-18].http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohyzs/s3586/201108/52675.htm.
    [11] COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease,a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial[J]. Chest,1994,105:1411.
    [12] Van Schayck CP,Folgering H,Harbers H,et al.Effects of allergy and age on responses to salbutamol and ipratropium bromide in? moderate asthma and chronic bronchitis[J]. Thorax,1991,46:355.
    [13] Tashkin DP,Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease:current and future agents[J]. Respir Res,2010,11:149.
    [14] Donohue JF,Fabbri C,Lotvall J,et al.Once-daily bronchodilators for chronic obstructive pulmonary disease:indacaterol versus tiotropium[J].Am J Respir Crit Care Med,2010,182:155.
    [15] Casaburi R,Mahler DA,Jones PW,et al.A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease[J].Eur Respir J,2002,19:217.
    [16] 陈新谦,金有豫,汤 光. 新编药物学[M]. 第17版.北京:人民卫生出版社,2011:446.
    [17] Calverley PM,Anderson JA,Celli B,et al.Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease[J].N Engl J Med,2007,356:775.
    [18] Szafranski W,Cukier A,Ramirez A,et al.Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease[J].Eur Respir J,2003,21:74.
    [19] Rabe KF.Update on roflumilast,a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease[J].Br J Pharmacol,2011,163:53.
    [20] Hansen NC,Skriver A,Brorsen-Riis L,et al.Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis[J].Respir Med,1994,88:531.
    [21] Zheng JP,Kang J,Huang SG,et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study):a randomised placebo-controlled study[J]. Lancet,2008,371,2013.
    [22] 朱 铮. COPD的药物治疗进展[J]. 临床肺科杂志,2011,16:585.
    [23] Jones PW,Harding G,Berry P,et al.Development and first validation of the COPD Assessment Test[J].Eur Respir J, 2009,34:648.
    [24] Hurst JR,Vestbo J,Anzueto A,et al.Susceptibility to exacerbation in chronic obstructive pulmonary disease[J].N Engl Med,2010,363:1128.
    [25] Anthonisen NR,Connett JE,Kiley JP,et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study[J]. JAMA,1994, 272:1497.
    [26] Berry MJ,Rejeski WJ,Adair NE,et al. Exercise rehabilitation and chronic obstructive pulmonary disease stage[J]. Am J Respir Crit Care Med,1999,160:1248.
    [27] Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines:recommendations of the Advisory Committee on Immunization Practices(ACIP),2009[J]. MMWR Recomm Rep,2009,58(RR08):1.
    [28] Hurst JR, Wedzicha JA.The biology of a chronic obstructive pulmonary disease exacerbation[J]. Clin Chest Med,2007,28:525.
    [29] Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations[J]. Am J Respir Crit Care Med,2006,173:1114.
    [30] Hurst JR, Wedzicha JA. Management and prevention of chronic obstructive pulmonary disease exacerbations:a state of the art review[J]. BMC Med,2009,7:40.
  • [1] 王洁, 卞莹莹, 张川, 开国银, 陆一鸣.  肿瘤坏死因子及其受体在类风湿性关节炎中的研究进展 . 药学实践与服务, 2017, 35(4): 289-293. doi: 10.3969/j.issn.1006-0111.2017.04.001
    [2] 张晋萍, 张海霞, 徐航, 卞晓洁, 杨贤, 方芸.  临床药师参与141例感染性疾病会诊的分析与体会 . 药学实践与服务, 2017, 35(1): 89-93. doi: 10.3969/j.issn.1006-0111.2017.01.023
    [3] 雷永芳, 凌青.  良性前列腺增生症的药物治疗及个体化用药 . 药学实践与服务, 2017, 35(5): 447-448,456. doi: 10.3969/j.issn.1006-0111.2017.05.015
    [4] 卞莹莹, 王洁, 李安, 开国银, 陆一鸣.  炎症性肠病的药物治疗现状 . 药学实践与服务, 2017, 35(3): 197-200,228. doi: 10.3969/j.issn.1006-0111.2017.03.002
    [5] 罗志成, 吴国振, 袁星.  慢性阻塞性肺疾病治疗药物研究进展 . 药学实践与服务, 2017, 35(3): 201-204,242. doi: 10.3969/j.issn.1006-0111.2017.03.003
    [6] 马宗强, 安洪亮.  门诊口服抗高血压药物的调查分析 . 药学实践与服务, 2016, 34(2): 188-190,192. doi: 10.3969/j.issn.1006-0111.2016.02.024
    [7] 赵佳丽, 陈秋红, 李红娜, 曾莉莉, 叶永贤, 费燕.  神经病理性疼痛的药物治疗进展 . 药学实践与服务, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006
    [8] 赵柳娅, 曹颖瑛, 姜远英.  两性霉素B联合用药的研究进展 . 药学实践与服务, 2014, 32(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2014.01.001
    [9] 陈翊, 濮剑英.  噻托溴铵对中重度慢性阻塞性肺病的治疗效果 . 药学实践与服务, 2012, 30(3): 213-215. doi: 10.3969/j.issn.1006-0111.2012.03.015
    [10] 丁晴雪, 栾智鹏, 陈盛新.  如何制定、实施和监测药物治疗方案 . 药学实践与服务, 2009, 27(4): 317-320.
    [11] 冯惠坚, 栾智鹏, 陈盛新.  医院药师如何开展循证药物治疗 . 药学实践与服务, 2009, 27(6): 476-480.
    [12] 傅翔, 栾智鹏, 陈盛新.  用药安全 . 药学实践与服务, 2009, 27(3): 236-240.
    [13] 陈盛新, 蒯丽萍, 舒丽芯.  药学服务的哲学思想与实施模式 . 药学实践与服务, 2007, (4): 268-272,199.
    [14] 佟雪菲, 陈盛新, 蒯丽萍, 忻伟明.  药学人力资源现状分析与开发对策 . 药学实践与服务, 2007, (2): 114-116.
    [15] 赵民生, 曹秀虹.  利尿剂在治疗心血管疾病时的不良反应及处理 . 药学实践与服务, 2006, (6): 353-354.
    [16] 张虹.  复方溶石剂一号的效果及安全性评价 . 药学实践与服务, 2005, (1): 24-27.
    [17] 徐国华, 雷招宝.  治疗慢性丙型肝炎新药——聚乙二醇干扰素α-2b . 药学实践与服务, 2005, (6): 350-353.
    [18] 唐斌, 何佩珍, 徐帆, 尚北城.  黄连素的联合用药 . 药学实践与服务, 2005, (5): 278-281.
    [19] 张生大.  双嘧达莫与其它药物合用的新用途 . 药学实践与服务, 2001, (1): 13-13.
    [20] 张铁俊, 张小莉, 王东文.  消化性溃疡临床用药 . 药学实践与服务, 1999, (2): 82-85.
  • 加载中
计量
  • 文章访问数:  13719
  • HTML全文浏览量:  424
  • PDF下载量:  2614
  • 被引次数: 0
出版历程
  • 收稿日期:  2012-03-02
  • 修回日期:  2012-05-28

慢性阻塞性肺疾病的药物治疗进展

doi: 10.3969/j.issn.1006-0111.2012.06.003

摘要: 慢性阻塞性肺疾病作为全球第四大死因,给公众的健康带来了严重威胁。适宜的慢性阻塞性肺疾病药物治疗能够预防和控制症状,减少急性加重的频率和严重程度,提高运动耐力和生活质量。合理使用作用机制不同、作用持续时间不同的药物,是当前慢性阻塞性肺疾病治疗的研究热点。本文综述近年来慢性阻塞性肺疾病的药物治疗进展及其治疗策略。

English Abstract

陈开宇, 江丽萍, 陈盛新. 慢性阻塞性肺疾病的药物治疗进展[J]. 药学实践与服务, 2012, 30(6): 408-411. doi: 10.3969/j.issn.1006-0111.2012.06.003
引用本文: 陈开宇, 江丽萍, 陈盛新. 慢性阻塞性肺疾病的药物治疗进展[J]. 药学实践与服务, 2012, 30(6): 408-411. doi: 10.3969/j.issn.1006-0111.2012.06.003
CHEN Kai-yu, JIANG Li-ping, CHEN Sheng-xin. Progress on drug treatment of chronic obstructive pulmonary disease[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(6): 408-411. doi: 10.3969/j.issn.1006-0111.2012.06.003
Citation: CHEN Kai-yu, JIANG Li-ping, CHEN Sheng-xin. Progress on drug treatment of chronic obstructive pulmonary disease[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(6): 408-411. doi: 10.3969/j.issn.1006-0111.2012.06.003
参考文献 (30)

目录

    /

    返回文章
    返回